|
covid-19 |
54 |
|
sars-cov-2 |
50 |
|
covid-19 vaccine |
39 |
|
mortality |
36 |
|
atrial fibrillation |
32 |
|
epidemiology |
32 |
|
bnt162b2 |
29 |
|
coronavac |
29 |
|
vaccine safety |
29 |
|
interprofessional education |
28 |
|
partnership model |
28 |
|
social interaction anxiety |
28 |
|
covid-19 vaccines |
27 |
|
public health |
27 |
|
stroke |
25 |
|
heart failure |
23 |
|
dementia |
22 |
|
sars-cov-2 infection |
21 |
|
pharmacoepidemiology |
20 |
|
secondary prevention |
19 |
|
type 2 diabetes |
19 |
|
inactivated vaccine |
18 |
|
self-controlled case series |
18 |
|
diabetes |
17 |
|
long covid |
17 |
|
myocardial infarction |
17 |
|
cardiovascular diseases |
16 |
|
aspirin |
15 |
|
cardiovascular disease |
15 |
|
cohort study |
15 |
|
ischemic stroke |
15 |
|
safety |
15 |
|
vaccine effectiveness |
15 |
|
cancer |
14 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
adverse events |
13 |
|
chinese |
13 |
|
cohort studies |
13 |
|
effectiveness |
13 |
|
major adverse cardiovascular events |
13 |
|
molnupiravir |
13 |
|
nirmatrelvir-ritonavir |
13 |
|
sex difference |
13 |
|
chronic diseases |
12 |
|
colorectal cancer |
12 |
|
ehr |
12 |
|
health services |
12 |
|
hong kong |
12 |
|
hyperthyroidism |
12 |
|
innate immunity |
12 |
|
non-communicable diseases |
12 |
|
tuberculosis |
12 |
|
anticoagulant |
11 |
|
chronic liver disease |
11 |
|
cirrhosis |
11 |
|
ckd |
11 |
|
clinical vertebral fractures |
11 |
|
graves disease |
11 |
|
hepatocellular carcinoma |
11 |
|
hip fractures |
11 |
|
hypertension |
11 |
|
hypothyroidism |
11 |
|
metformin |
11 |
|
multimorbidity |
11 |
|
older people |
11 |
|
omicron |
11 |
|
osteoporotic fractures |
11 |
|
paediatrics |
11 |
|
pasc |
11 |
|
post-covid-19 syndrome |
11 |
|
statistics & research methods |
11 |
|
thyroid dysfunction |
11 |
|
time in therapeutic range |
11 |
|
upper limb fractures |
11 |
|
warfarin |
11 |
|
all-cause pneumonia |
10 |
|
antiplatelet |
10 |
|
autoimmune disorders |
10 |
|
cost-effectiveness |
10 |
|
delirium |
10 |
|
depression |
10 |
|
electronic health records |
10 |
|
gastrointestinal haemorrhage |
10 |
|
herd immunity |
10 |
|
incident cvd |
10 |
|
interrupted time series analysis |
10 |
|
machine learning |
10 |
|
pharmacovigilance |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population-based electronic health records |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
post-covid cvd |
10 |
|
proton pump inhibitors |
10 |
|
real-world evidence |
10 |
|
statins |
10 |
|
adverse events of special interest (aesi) |
9 |
|
antibiotics |
9 |
|
asthma |
9 |
|
blood pressure |
9 |
|
cardiovascular complications |
9 |
|
diabetes mellitus |
9 |
|
infection |
9 |
|
microvascular complications |
9 |
|
pediatrics |
9 |
|
therapeutics |
9 |
|
vaccine |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
adverse events of special interest |
8 |
|
age-specific association |
8 |
|
antivirals |
8 |
|
biological sciences |
8 |
|
chinese medicine |
8 |
|
dabigatran |
8 |
|
drug regulatory |
8 |
|
drug utilization |
8 |
|
efficacy |
8 |
|
emulated trial |
8 |
|
geriatrics |
8 |
|
health equity |
8 |
|
health sciences |
8 |
|
mrna vaccine |
8 |
|
multiple organ complications |
8 |
|
myocarditis |
8 |
|
odds ratio |
8 |
|
orphan drug policy |
8 |
|
pediatric population |
8 |
|
pericarditis |
8 |
|
prescribing |
8 |
|
primary prevention |
8 |
|
rare diseases |
8 |
|
recurrent cardiovascular events |
8 |
|
risk prediction score |
8 |
|
severity |
8 |
|
treatment access |
8 |
|
trs 2°p |
8 |
|
adenocarcinoma |
7 |
|
adherence |
7 |
|
antiviral medications |
7 |
|
barriers |
7 |
|
cancer-associated venous thrombosis (cat) |
7 |
|
carbapenemase-producing enterobacteriaceae |
7 |
|
carriage |
7 |
|
colonoscopy |
7 |
|
dialysis patients |
7 |
|
direct oral anticoagulants (doacs) |
7 |
|
elderly |
7 |
|
focus group |
7 |
|
general practice |
7 |
|
glycated haemoglobin |
7 |
|
hospitalisation |
7 |
|
hypercholesterolemia |
7 |
|
lipid-lowering agents |
7 |
|
low-molecular-weight heparin (lmwh) |
7 |
|
markov state-transition model |
7 |
|
mental disorders |
7 |
|
nested case-control study |
7 |
|
peritoneal dialysis |
7 |
|
preferences |
7 |
|
primary health care |
7 |
|
quality-adjusted life years (qalys) |
7 |
|
renal replacement therapy |
7 |
|
risk factor |
7 |
|
type 2 diabetes mellitus |
7 |
|
vaccination |
7 |
|
visit‐to‐visit variability |
7 |
|
adult |
6 |
|
adverse drug reactions |
6 |
|
anti-coagulant |
6 |
|
antiepileptics |
6 |
|
antihypertensive drugs |
6 |
|
antimicrobial stewardship |
6 |
|
antipsychotics |
6 |
|
antiresorptives |
6 |
|
burden of disease |
6 |
|
cardiovascular event |
6 |
|
china |
6 |
|
chronic kidney disease |
6 |
|
cvd |
6 |
|
data repository |
6 |
|
disease and disorders of/related to bone |
6 |
|
doac |
6 |
|
elderly care |
6 |
|
gastroenterology |
6 |
|
gastrointestinal bleeding |
6 |
|
gastrointestinal tumours |
6 |
|
general diabetes |
6 |
|
general population studies |
6 |
|
glycemic control |
6 |
|
hdl‐c |
6 |
|
healthcare resource |
6 |
|
ldl‐c |
6 |
|
lipids variability |
6 |
|
lithium |
6 |
|
meta-data |
6 |
|
multinational cohort study |
6 |
|
neurogen |
6 |
|
neuroleptic agent |
6 |
|
neurological and mental health global epidemiology network |
6 |
|
non-st elevated myocardial infarction |
6 |
|
non-steroidal anti-inflammatory drugs |
6 |
|
nsaids |
6 |
|
pneumonia admission |
6 |
|
population aging |
6 |
|
preventive medicine |
6 |
|
primary care |
6 |
|
psychological symptoms |
6 |
|
respiratory tract infections |
6 |
|
self-controlled case series study |
6 |
|
st segment elevation myocardial infarction |
6 |
|
stomach cancer |
6 |
|
timi grading system |
6 |
|
variability |
6 |
|
adult cardiology |
5 |
|
algorithms |
5 |
|
angiotensin-converting enzyme inhibitors |
5 |
|
anticoagulation |
5 |
|
antiplatelets |
5 |
|
bacteria |
5 |
|
bleeding |
5 |
|
burden projection |
5 |
|
cancer incidence |
5 |
|
cancer risk |
5 |
|
cancers |
5 |
|
chemoprevention |
5 |
|
children |
5 |
|
chinese population |
5 |
|
clinical pharmacology |
5 |
|
clopidogrel |
5 |
|
cohort analysis |
5 |
|
colon cancer |
5 |
|
colonic neoplasms |
5 |
|
comorbidities |
5 |
|
comorbidity |
5 |
|
cost |
5 |
|
covid |
5 |
|
cvds |
5 |
|
donepezil |
5 |
|
drug escalation |
5 |
|
electronic health record |
5 |
|
enalapril |
5 |
|
global healthsales |
5 |
|
health policy |
5 |
|
hospitals |
5 |
|
inactivated vaccines |
5 |
|
income level |
5 |
|
inflammatory bowel disease |
5 |
|
insulin |
5 |
|
international normalized ratio |
5 |
|
interval cancer |
5 |
|
intracranial hemorrhage |
5 |
|
lipid-modifying agents |
5 |
|
long-term effect |
5 |
|
low-density lipoprotein cholesterol |
5 |
|
memantine |
5 |
|
meta-analysis |
5 |
|
non-vitamin k antagonist oral anticoagulants |
5 |
|
non-vitamin k oral anticoagulants |
5 |
|
non–vitamin k antagonist oral anticoagulants |
5 |
|
nsaid |
5 |
|
osteoporosis |
5 |
|
p2y12 inhibitors |
5 |
|
percutaneous coronary intervention |
5 |
|
pharmacoepidemiolgy |
5 |
|
post‐colonoscopy colorectal cancer |
5 |
|
propensity score |
5 |
|
readmission |
5 |
|
real-world data |
5 |
|
real‐life |
5 |
|
renin |
5 |
|
research design |
5 |
|
rivaroxaban |
5 |
|
rivastigmine |
5 |
|
sacubitril/valsartan |
5 |
|
sales trends |
5 |
|
short-acting β2 agonist |
5 |
|
systematic review |
5 |
|
telemonitoring |
5 |
|
thiazolidinediones |
5 |
|
time-varying markov model |
5 |
|
transient ischaemic attack |
5 |
|
treatment outcome |
5 |
|
treatment-resistant depression |
5 |
|
validation |
5 |
|
valvular heart disease |
5 |
|
accident and emergency department attendances |
4 |
|
adhd |
4 |
|
advanced kidney disease |
4 |
|
adverse outcome |
4 |
|
ageaged |
4 |
|
aggression |
4 |
|
amoxicillin/clavulanic acid |
4 |
|
anti-diabetic drug |
4 |
|
anticoagulant agent |
4 |
|
antimicrobials |
4 |
|
antiplatelet drugs |
4 |
|
arima |
4 |
|
asian population |
4 |
|
asians |
4 |
|
atherosclerotic cardiovascular disease |
4 |
|
atomoxetine |
4 |
|
attention deficit hyperactivity disorder |
4 |
|
bronchiectasis |
4 |
|
cancer epidemiology |
4 |
|
database |
4 |
|
deep learning |
4 |
|
deep vein thrombosis |
4 |
|
depression incidence forecasting |
4 |
|
diabetes complication |
4 |
|
dosing |
4 |
|
drug safety |
4 |
|
drug use |
4 |
|
dyslipidemia |
4 |
|
emergency medicine |
4 |
|
female |
4 |
|
fluoroquinolones |
4 |
|
gastric adenocarcinoma |
4 |
|
helicobacter pylori |
4 |
|
helicobacterpylori |
4 |
|
hospital admissions |
4 |
|
initiation |
4 |
|
insulin therapy |
4 |
|
latency interval |
4 |
|
medical informatics |
4 |
|
mental health |
4 |
|
meta-regression |
4 |
|
methylphenidate |
4 |
|
neuropsychiatric events |
4 |
|
oncology |
4 |
|
oral anticoagulant |
4 |
|
peptic ulcer |
4 |
|
pharmacy and pharmacology |
4 |
|
population-wide depression incidence |
4 |
|
pregnancy |
4 |
|
prevalence |
4 |
|
prevention |
4 |
|
prolactin |
4 |
|
psychotic disorders |
4 |
|
pulmonary embolism |
4 |
|
questionnaire |
4 |
|
renal failure |
4 |
|
repurposing |
4 |
|
retinal detachment |
4 |
|
rheumatoid arthritis |
4 |
|
sglt2 inhibitor |
4 |
|
statin |
4 |
|
stomach |
4 |
|
structural break scenarios |
4 |
|
substance use disorders |
4 |
|
sudden death |
4 |
|
survey |
4 |
|
taiwan |
4 |
|
target trial emulation |
4 |
|
temporal fusion transformers |
4 |
|
tofacitinib |
4 |
|
toxic epidermal necrolysis (ten) |
4 |
|
trend |
4 |
|
type 1 diabetes mellitus |
4 |
|
vector-arima |
4 |
|
venous thromboembolism |
4 |
|
violence |
4 |
|
women |
4 |
|
adolescents |
3 |
|
adults |
3 |
|
adverse drug event |
3 |
|
anticoagulation therapy |
3 |
|
antidepressant |
3 |
|
antipsychotic |
3 |
|
antirheumatic agents |
3 |
|
anxiety |
3 |
|
application |
3 |
|
arthritis |
3 |
|
attention-deficit/hyperactivity disorder |
3 |
|
bipolar disorder |
3 |
|
bones |
3 |
|
cholesterol |
3 |
|
chronic obstructive pulmonary disease |
3 |
|
cost-effectiveness analysis |
3 |
|
covid-19 infection |
3 |
|
deferasirox |
3 |
|
deferiprone |
3 |
|
deferoxamine |
3 |
|
dili |
3 |
|
direct oral anticoagulants |
3 |
|
drug costs |
3 |
|
drug efficacy |
3 |
|
drug side effect |
3 |
|
drug-induced liver injury |
3 |
|
electronic prescribing |
3 |
|
emergency department |
3 |
|
enjoying breathing program |
3 |
|
experiences |
3 |
|
fractures |
3 |
|
gastrointestinal absorption |
3 |
|
h2ra |
3 |
|
haemoglobinopathies |
3 |
|
health expenditures |
3 |
|
health information technology |
3 |
|
health literacy |
3 |
|
healthcare cost |
3 |
|
hepatotoxicity |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors |
3 |
|
impairment |
3 |
|
janus kinases |
3 |
|
liver function |
3 |
|
lorcaserin |
3 |
|
markov model |
3 |
|
medication regimen complexity |
3 |
|
meta‐analysis |
3 |
|
methodology |
3 |
|
methyl salicylate |
3 |
|
micronutrients |
3 |
|
observational study |
3 |
|
pharmaceutical preparations |
3 |
|
poisoning |
3 |
|
population screening |
3 |
|
ppi |
3 |
|
prescribing trend |
3 |
|
qualitative |
3 |
|
questionnaire survey |
3 |
|
questionnaires |
3 |
|
retina |
3 |
|
rheumatoid |
3 |
|
scale |
3 |
|
seizure |
3 |
|
stroke prophylaxis |
3 |
|
suicide & self-harm |
3 |
|
suicide attempt |
3 |
|
toxicokinetics |
3 |
|
treatment |
3 |
|
vaccines |
3 |
|
weight loss |
3 |
|
within-individual comparison |
3 |
|
acute agitation |
2 |
|
adverse event |
2 |
|
aged |
2 |
|
ages |
2 |
|
amfetamine |
2 |
|
anti-dementia medications |
2 |
|
asia |
2 |
|
autism spectrum disorder |
2 |
|
brain hemorrhage |
2 |
|
clostridium difficile |
2 |
|
emergency setting |
2 |
|
gastrointestinal ulcers (gius) |
2 |
|
global health |
2 |
|
gross domestic product |
2 |
|
histamine-2-receptor antagonists (h2ras) |
2 |
|
homes for the aged |
2 |
|
intramuscular sedatives |
2 |
|
methamfetamine |
2 |
|
multinational study |
2 |
|
naltrexone |
2 |
|
non-steroidal anti-infl ammatory drugs (nsaids) |
2 |
|
nursing homes |
2 |
|
pcv13 |
2 |
|
pharmaceutical services |
2 |
|
pharmacoeconomics |
2 |
|
pneumonia |
2 |
|
ppsv23 |
2 |
|
psychiatric emergency |
2 |
|
psychopharmacology; epidemiology |
2 |
|
sedation |
2 |
|
sequence symmetry analysis |
2 |
|
serotonin reuptake inhibitor |
2 |
|
ssri |
2 |
|
tolerability |
2 |
|
within-trial cost-effectiveness analyses |
2 |
|
absence of side effects |
1 |
|
acute disease |
1 |
|
aerosol |
1 |
|
agitation |
1 |
|
allied health personnel |
1 |
|
ambulance |
1 |
|
ambulances |
1 |
|
amiodarone |
1 |
|
analgesia |
1 |
|
antipsychotic agents - administration and dosage |
1 |
|
article |
1 |
|
assessment |
1 |
|
benzodiazepines - administration and dosage |
1 |
|
case report |
1 |
|
clinical feature |
1 |
|
coffee |
1 |
|
consent |
1 |
|
droperidol |
1 |
|
drug prescriptions |
1 |
|
drug substitution |
1 |
|
drug therapy, combination |
1 |
|
education |
1 |
|
emergency |
1 |
|
emergency care |
1 |
|
emergency health service |
1 |
|
emergency medical services |
1 |
|
emergency medical technician |
1 |
|
emergency service, hospital |
1 |
|
emergency services |
1 |
|
emergency ward |
1 |
|
ems |
1 |
|
fibrates |
1 |
|
general practitioner |
1 |
|
glycogen storage disease type 1 |
1 |
|
health care personnel |
1 |
|
health care quality |
1 |
|
health service |
1 |
|
heart arrest |
1 |
|
hospital |
1 |
|
hospital department |
1 |
|
hospital discharge |
1 |
|
hospital emergency department |
1 |
|
human |
1 |
|
laboratory test |
1 |
|
letter |
1 |
|
malaria |
1 |
|
male |
1 |
|
medical history |
1 |
|
medical staff |
1 |
|
medication errors |
1 |
|
methamphetamine |
1 |
|
midazolam |
1 |
|
multiple myeloma [mesh] |
1 |
|
olanzapine |
1 |
|
organization and management |
1 |
|
paramedic |
1 |
|
paranoia |
1 |
|
patient compliance |
1 |
|
patient referral |
1 |
|
pepper |
1 |
|
pharmaceutical preparation |
1 |
|
pharmacist |
1 |
|
pharmacy |
1 |
|
plasmodium falciparum |
1 |
|
police |
1 |
|
practice guideline |
1 |
|
prescription symmetry analysis |
1 |
|
psychomotor agitation |
1 |
|
psychomotor agitation - drug therapy |
1 |
|
quality control |
1 |
|
relapse |
1 |
|
restlessness |
1 |
|
restraint |
1 |
|
resuscitation |
1 |
|
schizophrenia |
1 |
|
schizophreniform disorder |
1 |
|
selinexor [mesh] |
1 |
|
sine compounds |
1 |
|
storage |
1 |
|
verbal de-escalation |
1 |
|
wandering behavior |
1 |
